For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 0 | 0* | 0 | 0 |
| Selling, general and administrative | 60,271 | -85,691 | 115,099 | 13,614 |
| Total operating expenses | 60,271 | -85,691* | 115,099 | 13,614 |
| Gain from operations | -60,271 | 85,691* | -115,099 | -13,614 |
| Liability forgiveness | - | 15,386.5* | - | - |
| Liability extinguishment | 20,000 | - | - | - |
| Interest expense - related parties | 3,503 | 2,167* | 2,710 | 1,948 |
| Total other expenses | - | - | 2,710 | 1,948 |
| Total other income (expense) | 16,497 | 13,219.5* | - | - |
| Gain before income tax expense | - | 98,910.5* | -117,809 | -15,562 |
| Income tax expense | - | 0* | 0 | 0 |
| Net gain | -43,774 | 98,910.5 | -117,809 | -15,562 |
| Diluted EPS | 0 | 0.002 | 0 | 0 |
| Diluted Average Shares | 60,042,000 | 60,042,000 | 60,042,000 | 60,042,000 |
ACRO BIOMEDICAL CO., LTD. (ACBM)
ACRO BIOMEDICAL CO., LTD. (ACBM)